It is small cap company listed on BSE and NSE and the company is engaged in the research, production and marketing business of second generation of antimalarial drugs. It has acquired the assets of Prophyla Biologicals (P) ltd
(including plant, machinery, land and building, furniture and fixtures, trade marks and other movables) situated in Pune district in 2010 and ventured into manufacturing of finished dosage formulations. It has also commenced production of third generation anti-malarial drugs in Mahad unit in Maharashtra. The company has received GMP certification for both the units at Mahad and Pune locations. Export status house has been awarded by Zonal joint director of foreign trade for 5 years valid up to 2015. The company has also obtained ISO 2200 2005 certification in 2010 for manufacturing and despatch of Quinine salts for its use as food additives.
The market capitalisation of the company is Rs.482,57 crores having PE ratio 13.40. The current market price of the scrip is Rs.383.70 as on 15.07.2011.
It is one of the companies which are long term bets for investment. The financials for the last 4 years are as given below:
| Figures in ` crores | FY 2010 | FY2009 | FY2008 | FY2007 |
| Income | 161.67 | 90.13 | 21.88 | 0 |
| Net Profit | 15.08 | 5.08 | 2.32 | 0 |
| Reserves & Surplus | 43.94 | 7.36 | 2.29 | -0.03 |
| Debt | 59.69 | 37.67 | 12.44 | 0.54 |
| Share capital | 5.78 | 4.95 | 2.00 | 0.01 |
The EPS of the company is Rs.26.11, Current ratio is 3.30 and return on long term funds is 26.43% as on 31.03.2010.
No comments:
Post a Comment